News

The label update includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
Phase 3 data show that ocrelizumab (Ocrevus) may delay the progression of disability, such as the need for a wheelchair, in patients with primary progressive multiple sclerosis (PPMS).
Quizartinib has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia.
Researchers investigated whether high body mass index is a risk factor not only for a greater risk of multiple sclerosis, but also for advancing to the secondary progressive stage of the disease.
A form of artificial intelligence known as a deep learning convolutional neural network outperformed dermatologists in diagnosing malignant melanomas.
Top news of the day from across the health care landscape
Researchers identified a promising biomarker for the PARP-inhibitor sensitivity in small cell lung cancer, which may help in determining the appropriate treatment for select patients.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$